In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment? @RheumNow #EULAR2025 #OP0330

Some RA-ILD is less of a worry, some is critical. How do we stratify? Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6. We need to do this more, so we can go really hard early when we need to. #EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2

• https://x.com/drdavidliew/status/1933462421408264623/photo/1

🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity: 💶Cost =barrier in 🇳🇱 ⛈️Weather =barrier in 🇹🇷 🧑‍⚕️HCP support =key in 🇫🇷 🏃Active transport & knowledge =enablers in 🇨🇭 Tailored physical activity interventions needed. @RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7

• https://x.com/DrMiniDey/status/1933463606147899562/photo/1

We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs: - lower inflamm - higher comorbidities Doesn’t necessarily map to fibromyalgia dx Beyond Rx, this is the critical question CareRA/2000 #EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb

• https://x.com/drdavidliew/status/1933465392296698091/photo/1
• https://x.com/drdavidliew/status/1933465392296698091/photo/1

Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025

📊 SIJ findings in PsA (n=581): 🧠 31% = MRI-confirmed axSpA 🦴 Only 29% met r-mNY criteria MRI-axPsA group: younger, more male, HLA-B27+ Clinical + radiographic definitely underperform vs MRI #POS0297 @RheumNow #EULAR2025

PsO + recent arthralgia—but no PsA. Treat or wait? 🧠 18% developed PsA in 3 yrs, most in year 1 🔍 Predictors: tender joints, disability, enthesis erosion Consider early rheum input for these patients Abstract POS0299 @RheumNow #EULAR2025

Can RZB deliver in real-world early PsA? 💥 9-month results say yes: ✅ Dactylitis gone in 79% ✅ Enthesitis in 90% ✅ 97% MDs & 88% pts satisfied Early intervention may pay off. Abstract POS0304 @RheumNow #EULAR2025

Very pleased to present at #EULAR2025 work @ArthritisAust on consumer involvement into research. Consumer involvement in research delivers: - better, more relevant research - better dissemination of results - competitiveness in today’s funding landscape POS1016-PARE @RheumNow https://t.co/0fhpsnGhdT

• https://x.com/drdavidliew/status/1933482629367804281/photo/1

High dose NSAIDs and incidence of HTN in axSpA? In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02). Interesting to

Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up? Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve

• https://x.com/drdavidliew/status/1933490836207251637/photo/1
• https://x.com/drdavidliew/status/1933490836207251637/photo/1

Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1

#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr

• https://x.com/Yuz6Yusof/status/1933491657250410888/photo/1

What is new in SpA? ‼️nomenclature change: 🚫AS≠ Ankylosing spondylitis ✅AS= Axial spondyloarthritis -Helena Marzo-Ortega at #EULAR2025 @RheumNow

Delay hurts. Dx delay in axial SpA costs UK £3.1 billion annually. Avg time to dx = 8.5 yrs Avg dx cost = £187k/person Fixing delay could save £167k/person. Early Dx isn’t just better care—it’s economic policy. #EULAR2025 @RheumNow #AxialSpA #RMD https://t.co/eYEQ2rp94m

• https://x.com/JihaRheum/status/1933492091457331458/photo/1